share_log

8-K: Notice of Guaranteed Delivery for Exercise of Warrants of Cassava Sciences

8-K: Notice of Guaranteed Delivery for Exercise of Warrants of Cassava Sciences

Cassava Sciences:Cassava Sciences行使认股权证保证交割通知
美股sec公告 ·  05/01 09:14
Moomoo AI 已提取核心信息
On May 1, 2024, Cassava Sciences, Inc., a clinical-stage biotechnology company, announced that May 2, 2024, would be the last day for trading its SAVAW warrants on NASDAQ. The company also reminded warrant holders that they have until 5pm New York time on May 6, 2024, to cash-exercise their warrants at $33.00 each, receiving 1.5 shares of common stock per warrant. After this deadline, any unexercised warrants will be redeemed by the company on May 7, 2024, for $0.001 per warrant. Cassava Sciences has provided a Notice of Guaranteed Delivery to assist warrant holders in exercising their warrants if their financial institution cannot complete the process timely. The company's press release and the Notice are available on its website and have been included in its SEC Form 8-K filing dated May 1, 2024. The announcement also refers to the company's mission to detect and treat neurodegenerative diseases, such as Alzheimer's disease.
On May 1, 2024, Cassava Sciences, Inc., a clinical-stage biotechnology company, announced that May 2, 2024, would be the last day for trading its SAVAW warrants on NASDAQ. The company also reminded warrant holders that they have until 5pm New York time on May 6, 2024, to cash-exercise their warrants at $33.00 each, receiving 1.5 shares of common stock per warrant. After this deadline, any unexercised warrants will be redeemed by the company on May 7, 2024, for $0.001 per warrant. Cassava Sciences has provided a Notice of Guaranteed Delivery to assist warrant holders in exercising their warrants if their financial institution cannot complete the process timely. The company's press release and the Notice are available on its website and have been included in its SEC Form 8-K filing dated May 1, 2024. The announcement also refers to the company's mission to detect and treat neurodegenerative diseases, such as Alzheimer's disease.
2024年5月1日,处于临床阶段的生物技术公司Cassava Sciences, Inc. 宣布,2024年5月2日将是其在纳斯达克交易SAVAW认股权证的最后一天。该公司还提醒认股权证持有人,他们必须在纽约时间2024年5月6日下午5点之前以每份33.00美元的价格兑现认股权证,每份认股权证获得1.5股普通股。在此截止日期之后,公司将在2024年5月7日以每份认股权证0.001美元的价格赎回所有未行使的认股权证。Cassava Sciences已提供担保交割通知,以帮助认股权证持有人在其金融机构无法及时完成认股权证流程时行使认股权证。该公司的新闻稿和通知已在其网站上发布,并已包含在2024年5月1日提交的美国证券交易委员会8-K表格中。该公告还提到了该公司的使命,即检测和治疗神经退行性疾病,例如阿尔茨海默氏病。
2024年5月1日,处于临床阶段的生物技术公司Cassava Sciences, Inc. 宣布,2024年5月2日将是其在纳斯达克交易SAVAW认股权证的最后一天。该公司还提醒认股权证持有人,他们必须在纽约时间2024年5月6日下午5点之前以每份33.00美元的价格兑现认股权证,每份认股权证获得1.5股普通股。在此截止日期之后,公司将在2024年5月7日以每份认股权证0.001美元的价格赎回所有未行使的认股权证。Cassava Sciences已提供担保交割通知,以帮助认股权证持有人在其金融机构无法及时完成认股权证流程时行使认股权证。该公司的新闻稿和通知已在其网站上发布,并已包含在2024年5月1日提交的美国证券交易委员会8-K表格中。该公告还提到了该公司的使命,即检测和治疗神经退行性疾病,例如阿尔茨海默氏病。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息